W. Jeffrey Fessel

Prof. Dr. W. Jeffrey Fessel

Medicine, University of California, San Francisco, San Francisco, California, USA
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2014 in JAMA
Verified
Journal Article
Open access
PDF file
MSMark S. Sulkowski
Mark S. Sulkowski
SNSusanna Naggie
Susanna Naggie
JLJacob Lalezari
Jacob Lalezari
WFW. Jeffrey Fessel
W. Jeffrey Fessel
KMKaram Mounzer
Karam Mounzer
FIfor the PHOTON-1 Investigators
for the PHOTON-1 Investigators
Up to 7 million persons worldwide are infected with both human immunodeficiency virus (HIV) and hepatitis C virus (HCV).1 Human immunodeficiency virus and HCV coinfection is associated with high rates of liver fibrosis, cirrhosis, hepatocellular carcinoma, and overall mortality.2 Coinfected patients who are cured of HCV have improved clinical outcomes and survival.3

1 December 2011 in Antiviral Research
Verified
Journal Article
Closed access
WFW. Jeffrey Fessel
W. Jeffrey Fessel
BABrooke Anderson
Brooke Anderson
SFStephen E. Follansbee
Stephen E. Follansbee
MWMark A. Winters
Mark A. Winters
SLStanley T. Lewis
Stanley T. Lewis
Robert W ShaferRobert W Shafer
Robert W Shafer

1 January 2019 in Alzheimer's & Dementia: Translational Research & Clinical Interventions
Verified
Journal Article
Open access
WFW. Jeffrey Fessel
W. Jeffrey Fessel
Several hundred clinical trials of initially promising drugs have failed to produce meaningful clinical improvement of Alzheimer's disease (AD), which is probably because there are at least 25 biochemical pathways known to be aberrant that underpin the disease, and unless there is a single drug that addresses all or most of them, even promising drugs if given alone are unlikely to succeed. Because so many pathways are potentially at fault, it is quite possible that no treatment might succeed. However, because amnestic mild cognitive impairment (aMCI) often precedes AD and, assuming that those with aMCI who progress to AD commence with insufficient risk factors for AD but accrue them later, then it is likely that fewer pathways need addressing in aMCI than in AD to either prevent progression of aMCI to AD or effect its reversion. Published reports show that eight drugs, that is, dantrolene, erythropoietin, lithium, memantine, minocycline, piracetam, riluzole, and silymarin, address many of the pathways underlying MCI and AD. Among those eight drugs, combinations between either two or three of them have combined nonoverlapping actions that benefit enough of the approximately 25 pathways at fault so that their convergent efficacy has the potential to prevent aMCI from progressing to AD. The combinations should be subjected to a clinical trial in persons with aMCI to establish their safety and efficacy.

25 March 2022 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
WFW. Jeffrey Fessel
W. Jeffrey Fessel
A puzzling feature of schizophrenia, is the long latency between the beginning of neuropathological changes and the clinical presentation that may be two decades later. Abnormalities in oligodendrocyte function may explain this latency, because mature oligodendrocytes produce myelination, and if myelination were abnormal from the outset, it would cause the synaptic dysfunction and abnormal neural tracts that are underpinning features of schizophrenia. The hypothesis is that latency is caused by events that occur in some patients as early as in-utero or infancy, because clones of abnormal, myelinating oligodendrocytes may arise at that time; their number doubles every ~2 years, so their geometric increase between birth and age twenty, when clinical presentation occurs, is about 1000-fold plus the effect of compounding. For those patients in particular, the long latency is because of a small but ongoing increase in volume of the resulting, abnormally myelinated neural tracts until, after a long latent interval, a critical mass is reached that allows the full clinical features of schizophrenia. During latency, there may be behavioral aberrancies because of abnormally myelinated neural tracts but they are insufficiently numerous for the clinical syndrome. The occurrence of behavioral symptoms during the long latent period, substantiates the hypothesis that abnormal oligodendrocytes explain the latency in some patients. Treatment with fingolimod or siponimod benefits both oligodendrocytes and neural tracts. Clinical trial would validate their potential benefit in appropriate patients with schizophrenia and, concurrently, would validate the hypothesis.

Verified
Journal Article
Open access
PDF file
WFW. Jeffrey Fessel
W. Jeffrey Fessel
Addressing the dysfunctions of all brain cell types in Alzheimer’s disease (AD) should cure the dementia, an objective that might be achieved by GLP-1 agonist drugs, because receptors for GLP-1 are present in all of the main brain cell types, i.e., neurons, oligodendroglia, astroglia, microglia, endothelial cells and pericytes. This article describes the benefits provided to all of those brain cell types by GLP-1 agonist drugs. The article uses studies in humans, not rodents, to describe the effect of GLP-1 agonists upon cognition, because rodents’ brains differ from those of humans in so many ways that results from rodent studies may not be totally transferable to humans. Commercially available GLP-1 agonists have mostly shown either positive effects upon cognition or no effects. One important reason for no effects is a reduced rate of entering brain parenchyma. Dulaglutide has the greatest entry to brain, at 61.8%, among the available GLP-1 agonists, and seems to offer the best likelihood for cure of AD. Although there is only one study of cognition that used dulaglutide, it was randomized, placebo controlled, and very large; it involved 8828 participants and showed significant benefit to cognition. A clinical trial to test the hypothesis that dulaglutide may cure AD should have, as its primary outcome, a 30% greater cure rate of AD by dulaglutide than that achieved by an equipoise arm of, e.g., lithium plus memantine.

16 May 2017 in International Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
PDF file
WFW. Jeffrey Fessel
W. Jeffrey Fessel